Safety and Tolerability Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Able to understand the study procedures and provide signed informed consent, which includes following the requirements in the informed consent form (ICF) and protocol. 2. Healthy male and female participants from 18 to 55 years, at the time of signing the informed consent. 3. Body weight of a minimum 50 kg for men and 45 kg for women and body mass index (BMI) within the range of 18.5 to 30 kg/m2. 4. Participants who are generally healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. 5. Contraceptive use by men or women consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants should be postmenopausal, surgically sterilized, or if of childbearing potential they must agree to use effective contraception throughout the study. Women of childbearing potential and those with less than 24 weeks from menopause must undergo a urine pregnancy test at screening and the result must be negative. 6. Participants must not eat Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices from 7 days before participants check into the clinical site until collection of the final sample. 7. Participants must not eat or drink caffeine- or xanthine-containing products (eg, coffee, black/green tea, cola drinks, and chocolate) or energy drinks for 48 hours before participants check into the clinical site until after collection of the final PK and/or PD sample. 8. Participants must nor drink alcohol for 24 hours before admission to the clinical site until after collection of the final PK and/or PD sample. Exclusion Criteria: 1. Major medical illness or unstable medical condition within 6 months of screening that affect the participant's ability to complete the study procedures follow restrictions, or affect the ability to interpret safety data that would prevent completion of study procedures or assessments. 2. Any clinically significant abnormal finding at physical examination. Absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. 3. Chronic or ongoing active infectious disease requiring systemic treatment 4. Any acute infections within 14 days of screening. 5. Vaccination received within 1 month of screening. 6. Participants known or suspected of not being able to comply with this study (eg, due to alcoholism, drug dependency or psychological disorder). 7. Any clinically significant lab abnormalities 8. Abnormal ECG findings 9. Abnormal screening estimated glomerular filtration rate 10. Positive test results for Hepatitis B, hepatitis C virus antibody, or human immunodeficiency virus (HIV). Negative evaluation for coronavirus disease 2019 (COVID-19). 11. History of significant allergic reactions to any drug. 12. Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives prior to the first dose of study drug 13. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, eg, acetylsalicylic acid) or selective serotonin reuptake inhibitors within 7 days prior to screening. 14. Positive urine cotinine test. Use of tobacco products or uses other nicotine-containing products from screening until final follow-up visit. Use of cigarettes 3 months before screening until final visit. 15. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women or 14 units for men of alcohol per week 16. History of drug abuse within 1 year prior to screening or recreational use of soft drugs within 1 month or hard drugs within 3 months prior to screening. |
Country | Name | City | State |
---|---|---|---|
United States | 1951 NW 7th Avenue, Suite 180 | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
MDI Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the incidence of treatment emergent adverse events [safety and tolerability] of a single-ascending oral dose of MDI-2517 in healthy participants | Adverse reactions to the study drug MDI-2517 will be measured | 5 days | |
Secondary | To evaluate the levels of MDI-2517 in blood plasma following a single oral dose of MDI-2517 in healthy participants | The levels of MDI-2517 in blood plasma following an oral single-dose of MDI-2517 tablets will be measured. | 5 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000891 -
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
|
Phase 1 | |
Active, not recruiting |
NCT05997641 -
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06181760 -
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05907382 -
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01952548 -
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT05431634 -
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT06331884 -
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
|
Phase 1 | |
Completed |
NCT03046589 -
DP13 SAD & MAD in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT06079541 -
Phase 1 Clinical Study of JMKX003142 Tablets
|
Phase 1 | |
Completed |
NCT05223660 -
A Phase I Pharmacokinetics Study for KT07 Capsule
|
Phase 1 | |
Completed |
NCT01907867 -
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
|
Phase 1 | |
Completed |
NCT03809052 -
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03853421 -
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
|
Phase 1 | |
Terminated |
NCT03307512 -
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
|
Phase 2 | |
Completed |
NCT03702231 -
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
Completed |
NCT03685708 -
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
Completed |
NCT03817346 -
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 | |
Completed |
NCT05451667 -
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02029482 -
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
|
Phase 1 |